icon star paper   Hepatitis B Articles (HBV)  
Back grey_arrow_rt.gif
 
 
New HBV Drugs / New /HBV-Cyclophillin Inhibitor
 
 
  Curing HBV, New Drugs - (01/22/15)
 
"in order to effectively clear an HBV infection and produce full remission, the viral cccDNA intermediates need to be destroyed"
 
"........any CURE of chronic hepatitis B will require elimination of cccDNA......cccDNA - HBV's largely unexplored persistence reservoir....." Jurgen Beck's talk see slide set in link above"
 
AASLD: Curing HBV....attacking cccDNA "Suppression of hepatitis B virus DNA accumulation in chronically infected cells using a bacterial CRISPR/Cas RNA-guided DNA endonuclease" - (01/12/15)
 
AASLD: Antiviral Therapy for Chronic Hepatitis B Reduces the Incidence of Hepatocellular Carcinoma Regardless of Cirrhosis Status: Analysis with Adjustment for REACH-B Risk Score - (12/21/15)
 
Johnson & Johnson Announces Completion Of Novira Therapeutics, Inc. Acquisition - (12/21/15)
 
------------------------
 
New HBV Drug Cyclophilin inhibitor CPI-431-32 in Pre-Clinical Development
 
http://www.ciclofilin.com/cpi-431-32.html
 
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0134707
 
http://www.journal-of-hepatology.eu/article/S0168-8278(15)31093-X/abstract
 
https://globenewswire.com/news-release/2015/06/24/747098/10139578/en/Ciclofilin-Pharmaceuticals-HBV-Drug-Demonstrates-Anti-Fibrotic-Activity.html
 
-------------------
 
MORE HBV Research
 
AASLD: Antiviral Activity of TAF Against Drug-Resistant HBV Isolates in Vitro - (01/07/16)
 
Gilead Announces Top-Line Results From Two Phase 3 Studies Evaluating Tenofovir Alafenamide (TAF) for Patients With Chronic Hepatitis B Infection - (01/05/16)
 
AASLD: Safety and Pharmacodynamics of Oral TLR-7 Agonist GS-9620 in Patients With Chronic Hepatitis B - (12/21/15)
 
AASLD: Functional Activation of Natural Killer and CD8+ T Cells by the Toll-Like Receptor 7 Agonist GS-9620 - (12/21/15)
 
AASLD: Cytokines Induced by a Toll-Like Receptor 7 Agonist Potently Inhibit HBV RNA, DNA, and Antigen Levels in Primary Human Hepatocytes - (12/21/15)
 
AASLD: Safety and Efficacy of GS-4774 in Patients With Chronic Hepatitis B on Oral Antiviral Therapy - (12/22/15)
 
AASLD: Tenofovir Disoproxil Fumarate Reduces Perinatal Transmission of Hepatitis B Virus in Highly Viremic Mothers: A Multicenter Randomized Controlled Study - (12/18/15)
 
AASLD: Integrated HBV DNA implicated in maintaining circulating HBsAg levels in chronically infected chimpanzees - (12/02/15)
 
AASLD: Monthly dosing of ARC-520 in chronically hepatitis B virus infected chimpanzees produces rapid, deep and durable reductions in circulating viral antigens - (12/02/15)
 
AASLD: Arrowhead Late-Breaking Clinical Data Shows that ARC-520 Can Produce Deep and Durable Reductions of Hepatitis B Viral Antigens and DNA - (12/02/15)
 
AASLD: ARC-520 produces deep and durable knockdown of viral antigens and DNA in a phase II study in patients with chronic hepatitis B - (12/02/15)
 
AASLD: Encapsidation and secretion of HBV RNA can be inhibited by Core Inhibitors but not by Nucleoside Analogs [NVR 3-778] - (12/02/15)
 
AASLD: Phase 1b Efficacy and Safety of NVR 3-778, a First-In-Class HBV Core Inhibitor, in HBeAg-Positive Patients with Chronic HBV Infection - (12/02/15)
 
AASLD: Inhibition of Hepatitis B Virus Replication by the HBV Core Inhibitor NVR 3-778 - (12/02/15)
 
Transgene Announces Dosing of First Patient with TG1050 for Treatment of Chronic Hepatitis B Infection - (11/05/15)

 
 
 
 
  icon paper stack View Older Articles   Back to Top   www.natap.org